All In Biotech

Investigational drug · Phase 2

ALTO-100

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Bipolar Disorder I or II With a Major Depressive Episode.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

4

Any phase or sponsor naming "ALTO-100"

First trial start

2024

Oct 2, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ALTO-100", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Bipolar Disorder I or II With a Major Depressive Episode

Approved drugs for the same conditions: Bipolar disorder · Psychiatry

Largest trials

Live from ClinicalTrials.gov: studies naming "ALTO-100" as an intervention, largest first.

All trials
  • Phase 2b Study of ALTO-100 in MDDPivotal-lookingCompleted

    Alto NeuroscienceIndustry

    NCT05712187 · 301 participants · Start Jan 10, 2023 · Primary completion Sep 5, 2024

    Drug: ALTO-100; Placebo · For: Major Depressive Disorder

    Sites: Birmingham, Alabama; Huntsville, Alabama; Chandler, Arizona · 34 sites in all

  • Alto NeuroscienceIndustry

    NCT05117632 · 245 participants · Start Dec 20, 2021 · Primary completion Dec 1, 2022

    Drug: ALTO-100 PO tablet · For: Major Depressive Disorder; Post Traumatic Stress Disorder

    Sites: Tempe, Arizona; Little Rock, Arkansas; Costa Mesa, California · 23 sites in all

  • Alto NeuroscienceIndustry

    NCT06656416 · 200 participants (planned) · Start Oct 2, 2024 · Primary completion Sep 2027

    Drug: ALTO-100; Placebo · For: Bipolar Disorder I or II With a Major Depressive Episode

    Sites: Birmingham, Alabama; Chandler, Arizona; Phoenix, Arizona · 68 sites in all

  • Alto NeuroscienceIndustry

    NCT05419869 · 21 participants · Start Jun 1, 2022 · Primary completion Jan 13, 2023

    Drug: ALTO-100 PO Tablet · For: Major Depressive Disorder

    Sites: Coral Gables, Florida; Jackson, Mississippi

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.